Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
CDMO
477 Articles Available
1
20
Can't find what you're looking for? Try our
advanced search
.
Cell and Gene Therapy
The Center for Breakthrough Medicines to Build a Cell and Gene Therapy CDMO in King of Prussia, PA
PR-M01-20-NI-035
CDMO
Yposkesi Selected to Produce Clinical and Large-Scale Commercial Material of Micro-Dystrophin for Genethon and Sarepta Therapeutics Program
PR-M01-20-NI-015
Microbiome
LNC Therapeutics Chooses Luina Bio for the Development and GMP Manufacturing of its First Live Biotherapeutic Product Based on the Gut Microbiome
PR-M01-20-NI-009
Project Management
Adhering to Delivery Milestones
PAP-Q4-19-CL-005
Investment in Innovation
Should You Choose a Commercial HPAPI Manufacturer for Your Clinical Program?
PAO-11-2019-CL-001
Launch
ANI Pharmaceuticals Announces the Launch of ANI Global Source, its Contract Development and Manufacturing Business
PR-M10-19-NI-049
Orphan Drugs
Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing
PAP-Q3-19-CL-013
Strategic Partnership
Growing With a Flexible, Collaborative CDMO
PAP-Q3-19-CL-014
Integration
True Integration is Integral to Providing One-Stop-Shop CDMO Services
PAP-Q3-19-CL-022
Capacity Utilization
Solving the Industry’s Capacity Utilization Problem
PAP-Q3-19-CL-033
Fermentation
Supporting Customers with an Integrated Fermentation Offering
PAP-Q3-19-CL-020
Contract Manufacturing
Avid Bioservices Enters into Contract Manufacturing Agreements with New and Existing Customers
PR-M07-19-NI-030
NDA
Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
PR-M07-19-NI-008
Plant-Based Innovation
The Advantage of Plant-Based Expression Solutions Around the Globe
PAO-M05-19-CL-002
Parenteral Manufacturing
Catering to a Growing Demand for Small-Volume Parenteral Manufacturing
PAO-M04-19-CL-001
Commercialization
Supporting Commercialization with Specialized Technologies
PAP-Q2-2019-CL-034
Business Development
Running a CDMO Business is Hard – So Now Let’s Talk about Value Creation
PAP-Q2-2019-CL-015
Customer Focus
Designing a Customer-Centric CDMO
PAP-Q2-2019-CL-003
Vaccine
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
PR-M05-19-NI-070
Commercialization
Adjusting Internal Structure to Better Meet Demands of Unmet Business
PAP-Q1-2019-CL-009
HPAPI
Successful US FDA Inspection of Asymchem Tianjin 1 HPAPI Development and Manufacturing Facility
PR-M03-19-NI-077
M&A
Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen To Accelerate Growth Of Its Bio CDMO Business
PR-M03-19-NI-043
Investment in Innovation
How Agile Investment Drives Innovation
PAP-Q1-2019-CL-004
HPAPI
Investing in the Future of Potent Compounds
PAP-Q1-2019-CL-028
1
20
»
